Skip to main content

Table 5 Univariate logistic regression analysis for long-term pancreatic adverse outcomes

From: Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury

Characteristic Odds ratio (95% confidence interval) P
Age 0.96 (0.92-1.02) 0.234
Male 2.60 (0.52-12.96) 0.244
Smoking 4.35 (1.06-17.81) 0.041
Alcohol 1.74 (0.48-6.24) 0.397
Hyperlipidemia 6.15 (1.24-30.55) 0.026
Prior history of pancreatitis 0.91 (0.10-8.24) 0.936
Pancreatic metastasis 0.61 (0.07-5.29) 0.654
CTLA-4–based regimena 1.54 (0.38-6.32) 0.549
Continued immune checkpoint inhibitor therapy 2.69 (0.72-10.04) 0.141
Time from initiation of immune checkpoint inhibitors to onset 0.99 (0.99-0.99) 0.016
Pancreatic symptoms 2.02 (0.40-10.13) 0.393
Peak lipase value 1.00 (0.99-1.01) 0.274
Peak amylase value 1.00 (0.99-1.01) 0.404
Abnormal computed tomography findings 0.49 (0.06-4.31) 0.519
Intravenous fluids 0.21 (0.06-0.79) 0.022
Fluid resuscitation volume 0.57 (0.16-1.99) 0.380
Steroids 1.44 (0.40-5.19) 0.572
Hospitalization 0.32 (0.04-2.66) 0.291
  1. aCTLA-4–based therapy included CTLA-4 monotherapy and combination of CTLA-4 and PD-1/L1 agents